Form 4: Amgen CEO Robert Bradway Reports Acquisition of 41,133 Shares of Common Stock

Amgen's CEO, Robert Bradway, reports acquiring 41,133 shares of common stock on March 6, 2024, bringing his total holdings to 683,910 shares.

Summary

• On March 6, 2024, Robert A. Bradway, the Chairman, CEO, and President of Amgen Inc., acquired 41,133 shares of Amgen's common stock.
• The acquisition was made directly, and the price per share was $0.
• Following the transaction, Bradway's total beneficial ownership of Amgen common stock is 683,910 shares.
• This total includes Restricted Stock Units (RSUs) that will vest at various dates in the future, as well as Dividend Equivalents (DEs) that are credited on unvested RSUs and paid out in shares of common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The CEO increasing his stake in the company is generally viewed favorably, but it's a routine transaction.

Positives

• The CEO's acquisition of a significant number of shares could be interpreted as a positive signal about his confidence in the company's future prospects.

Industry Context

This filing is a routine disclosure required by the SEC when a company insider, such as the CEO, trades in the company's stock. It provides transparency to the market regarding insider transactions.

Comparison to Industry Standards

• Executive stock ownership is common across the pharmaceutical industry.
• Comparing Bradway's holdings and recent transactions to those of CEOs at comparable companies like Johnson & Johnson, Pfizer, or Merck would provide a better understanding of whether his ownership stake is typical or atypical.
• The vesting schedules of the RSUs are also standard practice for executive compensation in the industry.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as it signals confidence from the CEO.

Key Dates